Kubesova, B
Pavlova, S
Malcikova, J
Kabathova, J
Radova, L
Tom, N
Tichy, B
Plevova, K
Kantorova, B
Fiedorova, K
Slavikova, M
Bystry, V
Kissova, J
Gisslinger, B
Gisslinger, H
Penka, M
Mayer, J
Kralovics, R
Pospisilova, S
Doubek, M
Article History
Received: 30 November 2016
Revised: 30 June 2017
Accepted: 5 July 2017
First Online: 24 July 2017
Competing interests
: HG: AOP Orphan, Calgene, Novartis—Consultancy, Honoraria, Research Funding and Speakers Bureau; JC: Honoraria and Speakers Bureau; Baxalta-Consultancy and Honoraria. MJ: Research Funding from AOP Orphan and Novartis. KR: Research Funding from AOP Orphan, a member on an entity’s Board of Directors or advisory committees in Qiagen. PM: AOP Orphan and Novartis—Consultancy, Honoraria, Research Funding and Speakers Bureau. DM: AOP Orphan, Novartis—Consultancy and Honoraria. The remaining authors declare no conflict of interest.